COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 8 of 334 for:    BENDAMUSTINE

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02433795
Recruitment Status : Completed
First Posted : May 5, 2015
Last Update Posted : December 3, 2020
Gyeongsang National University Hospital
Korea Cancer Center Hospital
Seoul National University Boramae Hospital
Hallym University Medical Center
Inje University
Gangnam Severance Hospital
Chonbuk National University Hospital
Chungnam National University
The Catholic University of Korea
Wonju Severance Christian Hospital
Gachon University Gil Medical Center
Seoul National University Bundang Hospital
Information provided by (Responsible Party):
Tae Min Kim, Seoul National University Hospital

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2019
Actual Study Completion Date : October 2019